Literature DB >> 21169873

Features of large cell transformation of indolent lymphomas as observed on sequential PET/CT.

Maroun Karam1, Paul J Feustel, Chido D Vera, Tipu Nazeer.   

Abstract

OBJECTIVE: Detection of large cell transformation (LCT) has been reported with the increasing use of PET/computed tomography (CT) in patients with indolent lymphomas. However, there is little information on PET/CT characteristics, specifically, the distribution of lesion maximum standardized uptake value (SUV(max)) within a patient, or SUV(max) changes before and after LCT. Our objectives were to compare SUV(max) values and distribution between nontransformed and LCT patients; to compare SUV(max) of LCT and nontransformed lesions in patients with documented focal transformation; and to measure the SUV(max) changes in patients before and after LCT.
METHODS: Retrospective study of patients with LCT (n=29)compared with nontransformed (n=41), and comparison of LCT and nontransformed lesions within patients and over time.
RESULTS: On average, the highest SUV(max) was greater in LCT patients than in nontransformed patients. In addition, there was a wider range of SUV(max) values in the LCT group compared with the nontransformed group (P<0.05). The median ratio of the SUV(max) of 12 LCT to nontransformed biopsy-proven lesions in the same patient was 4.3, P value of less than 0.05 (range 2.6-15.5). In 10 of 12 patients it was greater than or equal to 3. No change in highest SUV(max) and distribution was shown on serial PET in untreated nontransformed patients.
CONCLUSION: LCT is often focal and is associated with higher SUV(max) than nontransformed. The emergence of a focus with SUV(max) three times or higher than others on a single scan, or that has tripled or more in value on serial scans, should raise suspicion for LCT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21169873     DOI: 10.1097/MNM.0b013e328342b9d2

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

Review 1.  FDG PET-CT in follicular lymphoma: a case-based evidence review.

Authors:  Stephen D Smith; Mary Redman; Kieron Dunleavy
Journal:  Blood       Date:  2014-12-19       Impact factor: 22.113

2.  Improving the prognostic ability of PET/CT SUVmax to identify follicular lymphoma with early treatment failure.

Authors:  Xin Wan; Wei Guo; Xingtong Wang; Jia Li; Yangzhi Zhao; Xiaomeng Feng; Ken H Young; Ou Bai
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 3.  PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.

Authors:  Gita Thanarajasingam; Nabila Bennani-Baiti; Carrie A Thompson
Journal:  Curr Treat Options Oncol       Date:  2016-05

4.  Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.

Authors:  Farheen Mir; Sally F Barrington; Helen Brown; Tina Nielsen; Deniz Sahin; Michel Meignan; Judith Trotman
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

5.  Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma.

Authors:  Ajay Major; Andrew Hammes; Matthew Q Schmidt; Rustain Morgan; Diana Abbott; Manali Kamdar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-09-28

Review 6.  Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How.

Authors:  Francesca Pavanello; Sara Steffanoni; Michele Ghielmini; Emanuele Zucca
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-11-07       Impact factor: 2.576

7.  Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.

Authors:  Paolo Strati; Mohamed Amin Ahmed; Nathan H Fowler; Loretta J Nastoupil; Felipe Samaniego; Luis E Fayad; Fredrick B Hagemeister; Jorge E Romaguera; Alma Rodriguez; Michael Wang; Jason R Westin; Chan Cheah; Mansoor Noorani; Lei Feng; Richard E Davis; Sattva S Neelapu
Journal:  Haematologica       Date:  2019-10-10       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.